- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.07. | Longeveron Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 08.07. | Longeveron stock soars after FDA approves IND for heart failure treatment | 4 | Investing.com | ||
| 08.07. | Longeveron receives FDA approval for pediatric heart therapy IND | 2 | Investing.com | ||
| 08.07. | Longeveron Announces U.S. FDA Approval of IND Application for a Phase 2 Pivotal Registration Study Evaluating Laromestrocel as a Treatment of Pediatric Dilated Cardiomyopathy (DCM) | 243 | GlobeNewswire (Europe) | Accepted IND application allows for development program to move directly to a Phase 2 pivotal registration clinical trialPhase 2 clinical trial initiation anticipated in first half of 2026Pediatric... ► Artikel lesen | |
| 26.06. | Longeveron Appoints Than Powell as Chief Business Officer | 128 | GlobeNewswire (Europe) | Mr. Powell to oversee Longeveron's partnering and international strategy efforts MIAMI, June 26, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology... ► Artikel lesen | |
| 24.06. | Longeveron schließt Patientenrekrutierung für pädiatrische Herzstudie zu HLHS ab | 1 | Investing.com Deutsch | ||
| 24.06. | Longeveron completes enrollment in HLHS pediatric heart trial | 1 | Investing.com | ||
| 24.06. | Longeveron Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS) | 79 | GlobeNewswire (Europe) | Top-line trial results are anticipated in the third quarter of 2026, after the final follow-up at 12-monthsLaromestrocel Biological License Application (BLA) submission for full traditional approval... ► Artikel lesen | |
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| 20.06. | Longeveron Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 16.06. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.05. | Longeveron to Attend BIO International Convention 2025 | 7 | GlobeNewswire (USA) | ||
| 12.05. | Longeveron Named XPRIZE Healthspan Semifinalist and Top 40 Milestone 1 Award Recipient | 3 | GlobeNewswire (USA) | ||
| 08.05. | Longeveron Q1 2025 slides: promising clinical data amid financial headwinds | 1 | Investing.com | ||
| 08.05. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.05. | Longeveron Announces First Quarter 2025 Financial Results and Provides Business Update | 117 | GlobeNewswire (Europe) | Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to... ► Artikel lesen | |
| 08.05. | Longeveron Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 28.03. | Longeveron files $70M mixed securities shelf | 1 | Seeking Alpha | ||
| 20.03. | Longeveron Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer's Disease | 244 | GlobeNewswire (Europe) | Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer's diseaseAlignment with FDA on proposed trial study design... ► Artikel lesen | |
| 14.03. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.03. | Longeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's Disease | 228 | GlobeNewswire (Europe) | Phase 2a results demonstrated laromestrocel (Lomecel-B) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer's diseaseThis encouraging clinical trial data... ► Artikel lesen |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 94,40 | -2,13 % | DAX-Korrektur! BioTech Im Übernahme-Modus! BioNTech, CureVac, Pfizer, Vidac Pharma und Kraft Heinz im Fokus | Die Aktienmärkte zeigen sich in Bestform: Sowohl der DAX als auch der NASDAQ 100 haben in den vergangenen Tagen Muskeln gezeigt. Angetrieben werden die Kurse vor allem von der anhaltenden Stärke der... ► Artikel lesen | |
| CUREVAC | 4,610 | -0,43 % | CureVac-Timing ist alles - Warum heute ein Blick auf diese Aktie zählt!! | ||
| CRISPR THERAPEUTICS | 56,00 | 0,00 % | AKTIONÄR-Depotwert CRISPR Therapeutics: Aktie kommt in Fahrt - jetzt noch kaufen? | Die Aktie des AKTIONÄR-Depotwerts CRISPR Therapeutics hat sich in den vergangenen Wochen enorm stark entwickelt. Zuletzt hat sich die Aufwärtsbewegung sogar noch einmal beschleunigt. Seit dem Tief Anfang... ► Artikel lesen | |
| OCUGEN | 0,860 | -1,53 % | Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease | MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that... ► Artikel lesen | |
| CYTODYN | 0,248 | -1,59 % | CytoDyn Inc.: CytoDyn Announces Encouraging Survival Data in Patients with Metastatic Colorectal Cancer Previously Treated with Leronlimab | Positive results in patients with advanced mCRC emphasize potential significance of CytoDyn's ongoing Phase II CRC trial Dr. Benjamin Weinberg to present final results at the ESMO Gastrointestinal... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,051 | -5,94 % | SOL Global Investments Corp.: SOL Global Completes Debt Settlement Transaction, Provides Corporate Update and Dispute Settlement | Toronto, Ontario--(Newsfile Corp. - July 17, 2025) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), is pleased to announce, further to its previous news release... ► Artikel lesen | |
| CELLECTIS | 1,588 | +5,17 % | Cellectis Reports Financial Results for the First Quarter 2025 | Lasme-cel (UCART22) Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025Eti-cel (UCART20x22) Phase 1 study in relapsed or refractory B-cell non-Hodgkin lymphoma... ► Artikel lesen | |
| ANAVEX LIFE SCIENCES | 9,500 | +0,51 % | Anavex Life Sciences files $300M common stock offering | ||
| CERUS | 1,175 | -1,92 % | Cerus Corporation Provides INTERCEPT Red Blood Cell CE Mark Application Update | Cerus' Notified Body, TÜV-SÜD, has completed the review of the clinical module for the CE Mark submission for INTERCEPT Red Blood Cells (RBCs)
Cerus Corporation (Nasdaq: CERS) announced today a... ► Artikel lesen | |
| WINDTREE THERAPEUTICS | 1,190 | +13,33 % | Windtree Therapeutics: NBC kassiert +100% über Nacht! | Es ist der völlige Wahnsinn, was sich seit Wochen wieder im No Brainer Club abspielt. Hunderte Mitglieder scheinen aus dem Partymodus kaum noch herauszukommen: Der jüngste Trading-Tipp liefert mindestens... ► Artikel lesen | |
| APTEVO THERAPEUTICS | 2,500 | 0,00 % | Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules | SEATTLE, WASHINGTON / ACCESS Newswire / June 20, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based... ► Artikel lesen | |
| HARVARD BIOSCIENCE | 0,406 | +4,10 % | Harvard Bioscience, Inc.: Harvard Bioscience Announces CEO Succession Plan & Appointment of Two New Independent Directors to Board | Current Board member John Duke to succeed Jim Green as President & CEO Rob Gagnon and Seth Benson appointed as new Board membersQ2 '25 revenue anticipated to be $20.4 million and Company reiterates... ► Artikel lesen | |
| ENTERA BIO | 1,708 | +0,83 % | Entera Bio: Aktionäre genehmigen Vorstandswahl und Vergütungsvorschläge | ||
| XBRANE BIOPHARMA | 0,023 | 0,00 % | Xbrane Biopharma AB: Announcement from extra general meeting in Xbrane Biopharma AB | Today on 3 July 2025 the extra general meeting of Xbrane Biopharma AB (the "Company") was held and the following resolutions were passed by the meeting.
Resolution regarding approval of the board of... ► Artikel lesen | |
| QIAGEN | 41,405 | -0,35 % | Dividendenbekanntmachungen (10.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACCENTURE PLC IE00B4BNMY34 1,48 USD 1,2626 EUR AT&T INC US00206R1023 0,2775 USD 0,2367 EUR AZZ INC US0024741045 0,2 USD 0,1706... ► Artikel lesen |
LONGEVERON INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 1,540 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.